Researcher.Life Logo

Experimental Hematology and Oncology : Impact Factor & More

eISSN: 2162-3619pISSN: 2162-3619
JournalOpen Access

Key Metrics

CiteScore
8.1
Eigenfactor
0.001 - 0.005
Impact Factor
5 - 10
SJR
Q2Oncology
SNIP
1.39
Recommended pre-submission checks
Powered by Paperpal by Editage

Topics Covered on Experimental Hematology and Oncology

Experimental Hematology and Oncology Journal Specifications

Indexed in the following public directories

  • Web of Science Web of Science
  • Scopus Scopus
  • DOAJ DOAJ
  • SJR SJR
Overview
Publisher BMC
Language English
Frequency Continuous publication
Article Processing ChargesEUR 2590 | USD 2990 | GBP 2290
Publication Time6
Editorial Review ProcessAnonymous peer review
General Details
LanguageEnglish
FrequencyContinuous publication
Publication Start Year2012
Publisher URLVisit website
Website URLVisit website
Publication Details
PlagiarismVisit website
Publication Time 6
Waiver PolicyVisit website
Editorial Review Detail
Editorial TeamVisit website
Review ProcessAnonymous peer review
Review UrlVisit website
Information for authors
Author instructionsVisit website
Copyright DetailsVisit website
Deposit PolicySherpa/Romeo
License typeCC BY, CC0
OA statementVisit website
View less

Planning to publish in Experimental Hematology and Oncology ?

Upload your Manuscript to get

  • Degree of match
  • Common matching concepts
  • Additional journal recommendations
Free Report

Recently Published Papers in Experimental Hematology and Oncology

Crosstalk between ferroptosis and extracellular vesicles in cancer: from interaction to clinical application.
  • 11 Jan 2026
  • Experimental hematology & oncology
PRL-3 up-regulates exosomal ITGαvβ5 expression to promote liver pre-metastatic niche formation and colon cancer liver metastasis.
  • 8 Jan 2026
  • Experimental hematology & oncology
Hypoxia promotes BCMA loss and a suppressive secretome thereby hindering CAR T cell therapy in multiple myeloma
  • 8 Jan 2026
  • Experimental Hematology & Oncology
Synthetic essentiality of isoprenylcysteine carboxylmethyltransferase in PTEN deficient triple negative breast cancer
  • 8 Jan 2026
  • Experimental Hematology & Oncology
The lncRNA PARylator promotes PARP1 activation and resistance to DNA‑damaging therapy in esophageal squamous cell carcinoma.
  • 31 Dec 2025
  • Experimental hematology & oncology
Tetrahydromagnolol targets TRIM38 to mediate PANoptosis in cancer cells and has the potential for synergistic cancer therapy
  • 31 Dec 2025
  • Experimental Hematology & Oncology
Crosstalk between ferroptosis and extracellular vesicles in cancer: from interaction to clinical application.
  • 11 Jan 2026
  • Experimental hematology & oncology
PRL-3 up-regulates exosomal ITGαvβ5 expression to promote liver pre-metastatic niche formation and colon cancer liver metastasis.
  • 8 Jan 2026
  • Experimental hematology & oncology
Hypoxia promotes BCMA loss and a suppressive secretome thereby hindering CAR T cell therapy in multiple myeloma
  • 8 Jan 2026
  • Experimental Hematology & Oncology
Synthetic essentiality of isoprenylcysteine carboxylmethyltransferase in PTEN deficient triple negative breast cancer
  • 8 Jan 2026
  • Experimental Hematology & Oncology
The lncRNA PARylator promotes PARP1 activation and resistance to DNA‑damaging therapy in esophageal squamous cell carcinoma.
  • 31 Dec 2025
  • Experimental hematology & oncology
Tetrahydromagnolol targets TRIM38 to mediate PANoptosis in cancer cells and has the potential for synergistic cancer therapy
  • 31 Dec 2025
  • Experimental Hematology & Oncology

FAQs on Experimental Hematology and Oncology